BNTA|cas:685119-25-9|西域试剂

BNTA,99.53%

产品编号：Bellancom-136651| CAS NO：685119-25-9| 分子式：C₁₇H₁₁BrClNO₃S₂| 分子量：456.76

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-136651	￥3000.00	杭州北京（现货）
Bellancom-136651	￥5000.00	杭州北京（现货）
Bellancom-136651	￥9500.00	杭州北京（现货）
Bellancom-136651	￥15500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

BNTA

产品介绍

BNTA 是一种有效的细胞外基质 (ECM) 调节剂，通过激活超氧化物歧化酶 3 (SOD3) 促进软骨细胞上软骨结构分子的合成。BNTA 通过调节软骨生成显示了一种有希望的缓解骨关节炎的潜力。

生物活性

BNTA, a potent extracellular matrix (ECM) modulator, facilitates cartilage structural molecule synthesis on chondrocytes by activating superoxide dismutase 3 (SOD3). BNTA shows a promising potential for osteoarthritis alleviation by modulating cartilage generation.

体外研究

BNTA (0.01-10 μM; 1-7 d) does not decrease cell viability of human osteoarthritis chondrocytes and rat primary chondrocytes.
BNTA (0.1 μM; 2 d) increases SOX9 protein markedly.
BNTA (0.1 μM; 2 d) remarkably increases the COL2A1 and SOX9 protein levels in IL1β-induced rat OA chondrocytes.
BNTA (10 μM; 5 d) increases proteoglycan staining in ATDC5 cells.
BNTA (0.01-10 μM; 6 h) upregulates the expression levels of ECM-related genes COL2A1, ACAN, proteoglycan 4 (PRG4), and SRY-box 9 (SOX9) in human OA chondrocytes.
BNTA (0.01-10 μM; 6 h) increases Col2a1, Acan, Prg4, and Sox9 mRNA levels, with maximum effects around 0.1 μM in IL1β-induced rat OA chondrocytes.
BNTA (0.01-1 μM; 2 or 3 w) enhances anabolism and inhibited inflammatory response in osteoarthritis cartilage explants.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	Human OA chondrocytes
Concentration:	0.01, 0.1, 1, 10 μM
Incubation Time:	1, 3, 5, 7 d
Result:	No toxicity was observed.

Western Blot Analysis

Cell Line:	Human OA chondrocytes
Concentration:	0.1 μM
Incubation Time:	2 d
Result:	Elevated SOX9 protein compared with vehicle.

体内研究
(In Vivo)

BNTA (0.015-1.5 mg/kg; intra-articular injection; twice a week for 4 and 8 weeks) could attenuate OA progression developed after anterior cruciate ligament transection (ACLT) in rats.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male SD rats weighing 80 g are induced by ACLT
Dosage:	0.015, 0.15, 1.5 mg/kg
Administration:	Intra-articular injection; twice a week for 4 and 8 weeks
Result:	Attenuated post-traumatic osteoarthritis development after intra-articular injection for 4 and 8 weeks and was well tolerated.

体内研究

BNTA (0.015-1.5 mg/kg; intra-articular injection; twice a week for 4 and 8 weeks) could attenuate OA progression developed after anterior cruciate ligament transection (ACLT) in rats.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male SD rats weighing 80 g are induced by ACLT
Dosage:	0.015, 0.15, 1.5 mg/kg
Administration:	Intra-articular injection; twice a week for 4 and 8 weeks
Result:	Attenuated post-traumatic osteoarthritis development after intra-articular injection for 4 and 8 weeks and was well tolerated.

体内研究

BNTA (0.015-1.5 mg/kg; intra-articular injection; twice a week for 4 and 8 weeks) could attenuate OA progression developed after anterior cruciate ligament transection (ACLT) in rats.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male SD rats weighing 80 g are induced by ACLT
Dosage:	0.015, 0.15, 1.5 mg/kg
Administration:	Intra-articular injection; twice a week for 4 and 8 weeks
Result:	Attenuated post-traumatic osteoarthritis development after intra-articular injection for 4 and 8 weeks and was well tolerated.

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (218.93 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.1893 mL	10.9467 mL	21.8933 mL
5 mM	0.4379 mL	2.1893 mL	4.3787 mL
10 mM	0.2189 mL	1.0947 mL	2.1893 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (5.47 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (5.47 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (5.47 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (5.47 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。